Imperial Brands (IMB.L) — Company Research
Last Updated: 9 June 2026
Imperial Brands is one of the world's largest tobacco companies, the maker of cigarette brands including JPS, West, Davidoff, Winston and Gauloises, alongside a growing portfolio of next generation products (NGP) spanning vapour (blu), modern oral nicotine (Zone, Skruf) and heated tobacco (Pulze). The group also owns Logista, a leading pan-European tobacco and consumer-goods distribution business. Its FY2025 results (year ended 30 September 2025), published on 18 November 2025, marked the close of a five-year turnaround under former CEO Stefan Bomhard and the start of a new strategic chapter under Lukas Paravicini, who became Chief Executive in October 2025. The investment story is built on highly cash-generative combustible tobacco funding double-digit NGP growth, a progressive dividend and a large, ongoing share buyback. This report sets out the figures from primary company filings only, with no analyst opinions or price targets.
1. Company Snapshot
| Field | Value |
|---|---|
| Ticker | IMB.L (London Stock Exchange) / IMB |
| Index | FTSE 100 |
| Sector | Consumer Staples — Tobacco & Next Generation Products |
| Market cap | ~£21.1bn (June 2026) |
| Share price | 2,769p (last close, early June 2026) |
| Revenue (FY2025) | £32.17bn reported (incl. duty); £8.32bn tobacco & NGP net revenue |
| Adjusted operating profit (FY2025) | £3.99bn |
| Adjusted EPS (FY2025) | 315.0p |
| Dividend per share (FY2025) | 160.32p (yield ~5.8%) |
| CEO | Lukas Paravicini (since October 2025) |
| CFO | Murray McGowan |
| Employees | c. 25,600 (FY2024 disclosure) |
| Fiscal year end | 30 September |
| Headquarters | Bristol, United Kingdom |
2. Bull & Bear Case
Bull Case
- Exceptional cash generation: FY2025 free cash flow was £2.7bn against a market cap of ~£21bn, funding a 160.32p dividend (yield ~5.8%) and a £1.45bn buyback launched for FY26 — cumulative shareholder returns reached £10bn over FY21–FY25.
- Pricing power offsets volume decline: tobacco price/mix of 5.4% more than offset a 1.7% volume decline in FY2025, lifting tobacco & NGP net revenue 4.1% and demonstrating the resilience of the combustible model.
- NGP scaling profitably: NGP net revenue grew 13.7% to £368m in FY2025 (a fifth consecutive year of double-digit growth) while adjusted NGP losses narrowed to £76m, pointing to a path toward breakeven.
- Low-rated, shrinking share count: the shares trade on a single-digit forward earnings multiple while the buyback steadily reduces the share count, mechanically lifting adjusted EPS (up 9.1% in FY2025) on top of operating growth.
Bear Case
- Structural volume decline: cigarette volumes fall every year (-1.7% in FY2025); the entire bull case rests on pricing continuing to outpace volume erosion, which is not guaranteed indefinitely.
- Regulatory and excise risk: tobacco is exposed to flavour bans, generational sales bans (e.g. the UK), disposable-vape restrictions and ever-rising excise duty, any of which can compress volumes or margins.
- Reported profit volatility: reported operating profit fell 1.8% and reported EPS dropped 16.5% in FY2025 on impairments, FX and tax — the gap between adjusted and reported numbers can mask underlying pressure.
- Leverage and ESG constraints: reported net debt rose to £9.0bn (2.0x adjusted net debt/EBITDA) and ESG exclusion of tobacco caps the potential investor base, which can structurally suppress the rating.
3. Business Segments
Imperial reports two businesses — Tobacco & NGP (organised into three geographic segments) and Distribution (Logista). The table below shows each reportable segment's share of FY2025 group adjusted operating profit (£3,988m).
| Segment | % of adj. operating profit | What it is |
|---|---|---|
| Europe | 41.1% | UK, Germany, Spain, France, Italy and other European markets; the largest profit pool, £1,638m adjusted operating profit. |
| Americas | 30.9% | Primarily the USA (a key combustible market) plus the rollout of Zone modern oral nicotine; £1,233m adjusted operating profit. |
| AAACE | 19.9% | Africa, Asia, Australasia and Central & Eastern Europe; £794m adjusted operating profit, with strong NGP growth. |
| Distribution (Logista) | 7.9% | Pan-European logistics distributing tobacco and consumer goods; £316m adjusted operating profit, run on an operationally neutral basis. |
4. Business Model
Imperial Brands makes money by manufacturing and selling combustible tobacco and next generation nicotine products, and by distributing tobacco and adjacent products for third parties through Logista.
How it earns: the core engine is combustible tobacco, where Imperial follows a "challenger" strategy focused on five priority markets (USA, Germany, UK, Spain, Australia). Volumes decline structurally, but the group raises price faster than volumes fall — in FY2025 price/mix of 5.4% offset a 1.7% volume decline, growing tobacco net revenue 3.7%.
Unit economics: tobacco is exceptionally cash-generative because brands are established, marketing is restricted (limiting spend) and capital intensity is low — net capital expenditure was just £338m in FY2025 against £3.99bn of adjusted operating profit, producing £2.7bn of free cash flow.
Capital allocation: free cash flow funds a progressive dividend (160.32p in FY2025, up 4.5%), a multi-year buyback (£1.25bn completed in FY25, £1.45bn underway for FY26) and reinvestment in NGP and brand equity, while keeping leverage around 2.0x.
The NGP optionality: Imperial reinvests combustible cash into vapour (blu), modern oral (Zone, expanding to ~100,000 US stores) and heated tobacco (Pulze 3.0), aiming to build a profitable smoke-free business as the industry transitions.
5. Financial Health
All figures below are taken from Imperial Brands' full-year and half-year results statements (primary RNS filings). Revenue is reported revenue including tobacco duty; tobacco & NGP net revenue (excluding duty and Logista) was £8,316m in FY2025.
| Year | Revenue (£bn, incl. duty) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Net debt (YE, £bn) |
|---|---|---|---|---|---|---|
| FY2021 | £32.79bn | — | 299.9p | 246.5p | 139.08p | £9.37bn |
| FY2022 | £32.55bn | -0.7% | 165.9p | 265.2p | 141.17p | £8.49bn |
| FY2023 | £32.48bn | -0.2% | 252.4p | 278.8p | 146.82p | £8.44bn |
| FY2024 | £32.41bn | -0.2% | 300.7p | 297.0p | 153.42p | £8.34bn |
| FY2025 | £32.17bn | -0.7% | 251.1p | 315.0p | 160.32p | £8.95bn |
Imperial's earnings are heavily weighted to the second half of the fiscal year. The table below shows the most recent reported half (H1 FY2026, six months ended 31 March 2026) against the prior-year half and the FY2025 full year. Revenue shown is tobacco & NGP net revenue.
| Quarter / Half | Net revenue (T&NGP) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| H1 FY2026 (to 31 Mar 2026) | £3,729m | 127.7p | 59.9p |
| H1 FY2025 (to 31 Mar 2025) | £3,664m | 123.9p | 96.7p |
| Full year (FY2025) | £8,316m | 315.0p | 251.1p |
FY2025 cash flow and balance sheet (per the FY25 results statement): cash flows from operating activities £3,627m; net capital expenditure £338m; free cash flow £2,749m; adjusted EBITDA £4,299m; reported net debt £8,954m; cash and cash equivalents £1,439m; total borrowings £9,594m. The group's H1 FY26 interim dividend rose 4.0% to 83.36p.
6. Valuation
Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~£21.1bn |
| Trailing P/E (GAAP) | ~11.0x (price 2,769p / FY2025 reported EPS 251.1p) |
| P/E (forward) | ~8.1x (price 2,769p / FY2026 guided adjusted EPS ~340p, mid of high-single-digit growth on FY25's 315.0p) |
| P/S (TTM) | 0.66x (market cap £21.1bn / FY2025 reported revenue £32.17bn) |
| EV/EBITDA (TTM) | ~6.8x (EV ~£29.3bn / adjusted EBITDA £4.30bn; EBITDA = adjusted operating profit £3,988m + adjusted D&A £311m per FY25 cash flow statement) |
| P/FCF | ~6.4x (market cap £21.1bn / FCF £3.29bn; FCF = operating cash flow £3,627m − net capex £338m per FY25 cash flow statement; company-defined free cash flow after interest & minorities was £2,749m, implying ~7.7x) |
| Enterprise value | ~£29.3bn (market cap £21.1bn + total borrowings £9.59bn − cash £1.44bn per FY25 balance sheet; reported net debt £8.95bn) |
| 52-week high | 3,632p |
| 52-week low | 2,696p |
| Dividend yield | ~5.8% (160.32p / 2,769p) |
| Short interest (% of float) | Not published in US format for this LSE primary listing — the UK regime only requires net short positions ≥0.5% of issued capital to be disclosed to the FCA, and no individually disclosable short positions were on the FCA register as at June 2026. |
| Days to cover | Not published for LSE primary listing (see short interest note above) |
7. What They're Building
Imperial's forward agenda has two pillars: extracting sustainable value from combustibles and scaling next generation products. At its March 2025 Capital Markets Day the group set medium-term guidance for low-single-digit tobacco and double-digit NGP net revenue growth, with adjusted operating profit compounding and free cash flow of at least £2.2bn in FY26.
In NGP, Imperial runs a multi-category strategy. In vapour, it is expanding the pod-based blu kit range as the European market shifts to reusable devices. In modern oral nicotine, Zone is being rolled out aggressively in the USA (distribution expanded to around 100,000 stores) while Skruf and Zone grow in Europe. In heated tobacco, the recently launched Pulze 3.0 all-in-one device (used with iD and iSenzia sticks) is gaining share. Over the past five years cumulative NGP net revenue has grown 83% while NGP adjusted operating losses have been reduced 76%.
Under new CEO Lukas Paravicini, the group is pursuing an "evolutionary" version of the strategy: continued investment in consumer insight, innovation and marketing, plus a simplification programme — including a new ERP platform that went live at its first manufacturing site in October 2025 — designed to create a leaner, more agile organisation by 2030. You can monitor price action on our Live Charts page.
8. Competitive Landscape
Imperial is the smallest of the "big four" international tobacco majors by market value, competing on price-tier positioning and challenger agility rather than scale. The table compares the leading listed tobacco peers.
| Peer | Market cap (June 2026) | Key 2025 metric |
|---|---|---|
| Philip Morris International (PM) | ~$271bn | Global leader, driven by IQOS heated tobacco and ZYN modern oral nicotine. |
| British American Tobacco (BATS.L) | ~£107bn / ~$123bn ADR | Closest UK-listed peer; Vuse, glo and Velo power its "New Categories" business. |
| Altria (MO) | ~$116bn | US-focused (Marlboro domestic); on! oral nicotine and NJOY vapour. |
| Japan Tobacco (2914.T) | ~$50bn | Strong in emerging markets and Ploom heated tobacco; owns Camam/Winston internationally. |
9. Leadership & Ownership
Lukas Paravicini became Chief Executive Officer in October 2025, succeeding Stefan Bomhard who led the five-year turnaround. Murray McGowan is Chief Financial Officer. The Board and Chief Executive use adjusted operating profit as the main performance measure. Recent director (PDMR) activity has been concentrated in scheme-based long-term incentive awards rather than open-market purchases.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| Lukas Paravicini (CEO) | 16 Feb 2026 | LTIP award (grant) | 149,026 | n/a (nil-cost) | n/a (conditional) | FY26 Long Term Incentive Plan |
| Murray McGowan (CFO) | 16 Feb 2026 | LTIP award (grant) | 58,926 | n/a (nil-cost) | n/a (conditional) | FY26 Long Term Incentive Plan |
These FY26 LTIP awards vest subject to performance conditions including adjusted EPS growth, return on invested capital, cumulative free cash flow, relative total shareholder return and ESG targets. No material open-market insider purchases or disposals were disclosed via RNS during the period.
10. Risks
- Regulatory (high relevance): flavour and disposable-vape bans, generational tobacco sales bans (notably in the UK), plain packaging and advertising restrictions can each reduce volumes or raise compliance costs.
- Excise & taxation: tobacco duty rises in high-excise markets can accelerate volume declines and shift consumers to illicit trade, pressuring net revenue.
- Structural volume decline: combustible cigarette volumes fall every year; the model depends on pricing continuing to more than offset this, which may not hold in a downturn.
- NGP execution: next generation products are competitive and loss-making at the group level (£76m adjusted loss in FY2025); failure to reach scale or profitability would undermine the long-term transition.
- FX translation: a large share of profit is earned in US dollars and euros; adverse currency moves reduce reported revenue, profit and EPS (a headwind in FY2025).
- Leverage & capital returns: reported net debt of £9.0bn (2.0x EBITDA) means rising rates or weaker cash flow could constrain the buyback and dividend.
- Litigation & ESG: tobacco litigation and ESG-driven investor exclusion can cap the valuation multiple and limit the buyer base.
11. Recent Developments
- 18 Nov 2025 — FY2025 full-year results. Tobacco & NGP net revenue up 4.1%, adjusted operating profit up 4.6%, adjusted EPS up 9.1% to 315.0p; dividend raised 4.5% to 160.32p; reported revenue £32.17bn; free cash flow £2.7bn.
- 18 Nov 2025 — FY26 buyback launched. The £1.25bn FY25 buyback was completed and a new £1.45bn buyback for FY26 commenced, taking cumulative FY21–FY25 returns to £10bn.
- 1 Oct 2025 — CEO transition. Lukas Paravicini took over as Chief Executive from Stefan Bomhard, beginning an "evolutionary" next phase of strategy.
- 16 Feb 2026 — FY26 LTIP grants. The Board granted long-term incentive awards to executive directors, including 149,026 shares to the CEO and 58,926 to the CFO.
- 12 May 2026 — H1 FY2026 half-year results. Tobacco & NGP net revenue up 1.8% to £3,729m, NGP net revenue up 7.5%, adjusted EPS up 5.3% to 127.7p; interim dividend up 4.0% to 83.36p; FY26 guidance reaffirmed.
12. Key Dates
- 20 Aug 2026 — expected ex-dividend date (FY26 quarterly dividend)
- 30 Sep 2026 — FY2026 financial year end
- Expected Nov 2026 — FY2026 full-year results announcement
- Expected Jan 2027 — Annual General Meeting
Track scheduled market-moving events on our Economic Calendar, and discuss this research with other investors on the ChartsView Forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. Imperial Brands manufactures and sells combustible tobacco and next generation nicotine products and distributes tobacco for third parties through Logista, earning the bulk of its profit from highly cash-generative cigarettes. In FY2025 (year ended 30 September 2025) reported revenue was £32.17bn, tobacco & NGP net revenue grew 4.1%, adjusted operating profit rose 4.6% and adjusted EPS climbed 9.1% to 315.0p, with free cash flow of £2.7bn funding a 160.32p dividend and a £1.45bn FY26 buyback. Management guides to low-single-digit tobacco and double-digit NGP net revenue growth, with pricing continuing to more than offset cigarette volume decline.
What would confirm or break it. Continued pricing power that outpaces cigarette volume decline, NGP losses narrowing toward breakeven, and sustained buyback-driven EPS growth would confirm the case. The thesis would weaken if tobacco regulation or rising excise accelerates volume erosion, if NGP fails to scale, or if adverse FX and £9.0bn of net debt constrain the dividend and buyback programme.
Watchpoints
- ConfirmsFY2026 full-year results (161 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Exceptional cash generation:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Regulatory (high relevance):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 9 Jun 2026.